The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.
复制标题
DOI：
10.1016/j.jalz.2015.05.001
复制
发表时间：
2015-07
期刊：
影响因子：
--
通讯作者：
Wang AY
中科院分区：
文献类型：
--
作者：
Jagust WJ;Landau SM;Koeppe RA;Reiman EM;Chen K;Mathis CA;Price JC;Foster NL;Wang AY
本文回顾了过去5年中ADNI PET核心所做的工作，主要涉及与ADNI中淀粉样蛋白成像有关的技术，方法和结果。
宠物核心已在ADNI参与者身上常规使用[18F] Florbetapir，可下载1600多个扫描。数据分析涉及四个不同的实验室，并检查了诸如纵向Florbetapir分析，FDG-PET在临床试验中的使用以及不同生物标志物与认知之间的关系等因素。
来自宠物核心的融合证据表明，横截面和纵向的Florbetapir分析需要不同的参考区域。研究还检查了注射后立即获得的Florbetapir数据之间的关系，这反映了灌注，FDG-PET结果。最后，标准化包括将Florbetapir PET数据转换为Centiloid量表。
宠物核心已经证明了在多中心环境中生物标志物（例如Florbetapir PET）标准化的多种方法。
This paper reviews the work done in the ADNI PET core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI. The PET Core has utilized [18F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of FDG-PET in clinical trials, and relationships between different biomarkers and cognition. Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale. The PET Core has demonstrated a variety of methods for standardization of biomarkers such as florbetapir PET in a multicenter setting.